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Abstract 
Purpose. Catheter ablation of the slow pathway is the most effective treatment for atrioventricular 
nodal reentrant tachycardia (AVNRT). Cryoenergy, compared to radiofrequency, relates to lower 
heart block risk, but higher incidence of AVNRT recurrences. The aim of this study is to confirm 
safety and efficacy of AVNRT cryoablation and to identify predictors of long-term recurrences. 
Methods and Results. Among 241 patients undergoing AVNRT cryoablation, 239 (99.2%) 
experienced acute effective cryoablation of the slow pathway, and no procedure-related 
complications were reported. After a follow-up of 44.9±31.7 months, 28 (11.7%) patients presented 
AVNRT recurrences. A shorter pre-ablation (p=0.05) and post-ablation anterograde Wenckebach 
cycle length (p<0.01), a shorter post-ablation atrioventricular node refractory period (p= 0.04) and 
persistence of the crossover sign (p= 0.03) were associated with higher incidence of long-term 
recurrences. Considering cooling dynamics, a longer time to reach temperature ≤-70°C (p= 0.03) 
and a higher minimal temperature during ablation (p= 0.04) related to recurrences. Patients without 
residual markers of dual AV node physiology (AH jump, single atrial echo beat, crossover) reported 
a lower recurrence rate (p=0.05) compared to those without. At multivariate analysis, a longer time 
to -70°C was the strongest independent predictor of long-term recurrence (OR 1.75, 95% IC 1.01 - 
3.03, p= 0.04). 
Conclusions. AVNRT cryoablation is safe and effective. Long-term recurrence rate was 11.7%. An 
ablation approach directed to the complete elimination of dual AV node physiology, along with 
assessment of tissue’s cooling dynamics, hold the potential to improve long-term AVNRT 
cryoablation efficacy. 
Abstract word count: 244
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Introduction 
Atrioventricular nodal reentrant tachycardia (AVNRT) is the most common paroxysmal 
supraventricular tachycardia. The underlying electrophysiological mechanism is the presence of a 
dual atrioventricular (AV) node physiology, including a fast and a slow pathway [1], characterized 
by different refractory periods. Dual AV node physiology is a frequent finding, being described in 
up to 90% of patients in a small case sample of heavily sedated patients undergoing 
electrophysiological study (EPS) [2], but does not always imply an AVNRT. Radiofrequency 
transcatheter ablation (RFCA) of the slow pathway is at present considered the first choice 
treatment for AVNRT because of its high acute and long-term efficacy [3]. Although RFCA is 
widely used, it is still associated with a risk of irreversible complete AV block (up to 1-2%) [4]. 
Transcatheter cryoablation of the slow pathway has been demonstrated to be a feasible and safe 
alternative to RFCA, with no permanent AV block reported and a comparable acute success rate [5-
7]. In fact, reversible cryomapping permits to evaluate the safety of the site targeted for ablation, 
leading to a return to integrity in case of AV block development [8]. However, the long-term 
recurrence rate of this technique remains higher than RFCA [9,10]. 
Previous studies focused on identifying factors that could affect acute and long-term efficacy, such 
as catheter tip size [11], electrophysiological markers of residual dual AV node physiology [11,12], 
duration and number of cryoenergy applications [13], but data are limited and sometimes 
controversial, and no strong predictor of cryoablation long-term efficacy has been identified [14-
16]. The aim of this study is to evaluate the safety, acute and long-term efficacy of AVNRT 
cryoablation and to identify intra-procedural predictors of long-term efficacy, focusing on both 
electrophysiological parameters and cooling dynamics.  
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Methods  
We retrospectively analyzed all patients with diagnosis of AVNRT confirmed by EPS who 
underwent transcatheter cryoablation of the slow pathway from June 2005 to March 2015 in two 
high volume Centers, both performing cryoablation as a standard first-line approach for AVNRT 
ablation. Inclusion criteria were: one or more previously documented episodes of AVNRT (12-leads 
ECG or Holter ECG monitoring documentation), clinical response to vagal manoeuvers and/or i.v. 
adenosine or AV node blocking drugs, and written informed consent to undergo the ablation 
procedure. Patients in whom cryoablation was performed using a 4-mm tip catheter, previously 
described as less effective than 6-mm tip, were excluded from the analysis.  
 
Electrophysiological study and cryoablation procedure 
Written informed consent was obtained from all individual participants included in the study. A 
standard EPS including ventricular and atrial programmed and incremental stimulation, was 
performed to evaluate dual AV node physiology and confirm the diagnosis of AVNRT. All 
antiarrhythmic drugs (AAD) were discontinued for at least five half-lives before EPS. Diagnostic 
catheters were positioned in His bundle region, right ventricular apex and coronary sinus through a 
venous femoral approach. Recently, NavX (St. Jude Medical, St. Paul, MN, USA) system was used 
in order to minimize the use of fluoroscopy and to perform a right atrium electroanatomical map 
[17]. 
Dual AV nodal physiology was defined as the presence of a ≥50 ms increase in A2H2 in response 
to a 10 ms decrease of the extrastimulus at programmed atrial or ventricular stimulation (jump). 
Incremental atrial stimulation was performed to assess anterograde Wenckebach cycle length and 
the PR to RR interval ratio at the maximum rate with consistent 1:1 AV conduction (a PR to RR 
ratio higher than 1 at the maximal 1:1 AV conduction heart rate will be referred as crossover sign) 
[18,19]. 
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If sustained AVNRT was not inducible, intravenous isoproterenol was administered to facilitate 
induction until a 20% increase in baseline heart rate was detected. After tachycardia induction, a 
single premature ventricular extrastimulus was administered to rule out the presence of an accessory 
pathway and to confirm the subtype (typical vs atypical) of the AVRNT. Patients in whom 
sustained AVNRT was not inducible slow pathway ablation was performed only in case of 
undoubtful 12-leads ECG documentation of AVNRT and concomitant dual AV node physiology 
(AH jump, echo beats and crossover sign). Subsequently, a 6-mm cryocatheter (Freezor Xtra, 
Cryocath Technologies, Medtronic, Montreal, Canada) was used to perform slow pathway 
cryoablation. An electroanatomical approach was applied to identify the target site through the 
recording and validation of slow pathway potential [20]. 
Cryomapping (-30 °C for 60 sec) was performed in order to verify safety and efficacy of the site. In 
case of successful cryomapping (AVNRT non-inducibility or absence of dual AV nodal physiology 
without affecting anterograde AV conduction), cryoablation was performed (-75/-80°C) by a single 
8-minutes application to create a permanent lesion; a 4-minutes bonus lesion was always applied in 
an adjacent site [21]. EPS on and off isoproterenol was repeated 20 minutes after cryoablation to 
assess non-inducibility of AVNRT and absence of dual AV node physiology; residual AH jump 
with or without a single nodal echo beat was accepted only in cases where a previously inducible 
AVNRT was not anymore inducible, on and off isoproterenol. Baseline and post-ablation EPS 
parameters were recorded and analyzed for all patients. 
Additionally, cooling dynamics characteristics of the effective cryoenergy application (defined as 
the application immediately followed by dual AV node physiology disappearance or slow pathway 
significant modulation, i.e., disappearance of AVNRT induction, echo beats, AH jump or crossover 
sign), including time to reach the therapeutic temperature of -70°C starting from cryomapping, the 
minimal temperature during ablation and the presence/absence of a temperature curve inversion 
during progression from cryomapping to cryoablation were analyzed in all procedures. 
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All the patients were discharged without AAD the day after procedure, and underwent clinical 
evaluation, including ECG and 24h-Holter recording at 3, 6 and 12 months after cryoablation. In 
case of documented AVNRT recurrence, a new cryoablation procedure was planned. An additional 
follow-up visit was performed at the end of follow-up.  
 
Statistical analysis 
Continuous data, expressed as means ± standard deviation (SD), were compared by one-way 
ANOVA test after normal distribution was confirmed. Categorical variables, presented as counts 
and percentages, were compared in cross-tabulation tables by Pearson’s chi-square test. Following 
univariate analysis, all parameters with associated p value <0.05 were tested in a multivariable 
logistic regression model used to determine the association between baseline and procedural 
characteristics and arrhythmic recurrences during follow-up. All tests of significance were two-
tailed, and a p value <0.05 was considered statistical significant. All analyses were performed using 
SPSS 21.0. 
 
 
Results 
Study population included 241 patients with symptomatic episodes of AVNRT who underwent 
cryoablation of the slow pathway. Acute success was achieved in 239 patients (99.2%). During a 
mean follow-up of 44.9 ± 31.7 months, 28 (11.7%) patients experienced AVNRT recurrence.   
Mean age was 47.5 ± 19.7 years, and 149 (61.8%) patients were females. Most patients (92.5%) did 
not have structural heart disease, or any other associated arrhythmia. Fifty-seven (23.7%) patients 
suffered from hypertension, 5 (2.1%) from hyperthyroidism and 13 (5.4%) from hypothyroidism.  
AAD therapy before cryoablation included beta-blockers in 107 (44.4%) patients, Calcium channel 
blockers in 25 (10.4%) patients and class Ic AAD in 48 (19.9%) patients. Typical (slow-fast) 
AVNRT was diagnosed in 229 (95%) patients. Baseline characteristics are shown in Table 1. 
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In 203 (84.9%) patients sustained AVNRT was induced during EPS, off (79%) or on (21%) 
isoproterenol infusion. All patients presented a dual AV node physiology, in baseline study or 
during isoproterenol infusion. Due to the undoubtful ECG documentation and the presence of dual 
AV node physiology at EPS, slow pathway ablation was performed also in the 36 (15.1%) patients 
without sustained AVNRT induction. Recurrence rate did not differ between patients in which 
sustained AVNRT was induced or not at EPS (p=0.19). Baseline EPS parameters are reported in 
Table 2. 
A median of 3.3 ± 2.8 cryoenergy applications were performed per patient, with a mean duration of 
7.8 ± 0.5 min. Mean fluoroscopy time was 4.5 ± 5.0 min. Cooling dynamics characteristics, in 
particular time to reach the target temperature of -70°C, minimal temperature reached and 
presence/absence of a transitory temperature curve inversion are reported in Table 3. None of the 
patients had procedure-related complications, in particular no AV conduction abnormalities were 
reported. 
At post-ablation EPS (Table 4), 51 (21.3%) patients reported a residual AH jump, 19 (7.9%) a 
single nodal echo beat, and 9 (3.8%) residual crossover sign. AV nodal anterograde refractory 
period was 312.6 ± 77.5 ms after cryoablation, and the anterograde Wenckebach cycle length 370.4 
± 82.2 ms. At the end of the procedure in 238 (99.2%) patients AVNRT was not inducible on and 
off isoproterenol, and the procedure was considered effective. AVNRT was still inducible in one 
patient, in whom modulation of the slow pathway was performed (this patient did not suffer 
recurrences during follow-up). 
 
Predictors of recurrence 
No differences were observed in baseline clinical characteristics between patients who had or not 
recurrences. Considering cooling dynamics, a longer time to reach a temperature ≤ -70°C during 
ablation (8.9 ± 4.4 vs 7.3 ± 2.5 sec, p= 0.03) and a higher minimal temperature during ablation (-78 
± 2.5 vs -79.2 ± 2.3 °C, p= 0.04) related to a higher incidence of AVNRT recurrence. As shown in 
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the Kaplan-Meier estimate of survival (Figure 1), patients without any marker of residual dual AV 
node physiology (AH jump, single nodal echo beat, crossover sign) at final EPS reported a lower 
recurrence rate (p=0.05) compared to patients with at least one of these markers. 
At multivariate analysis, a longer time to -70°C proved to be the strongest independent predictor of 
long term recurrence (OR 1.75, 95% IC 1.01 - 3.03, p= 0.04) (Table 5). 
Additionally, a shorter pre-ablation (325.4 ± 54.02 vs 356.9 ± 76.3 ms, p= 0.05) and post-ablation 
anterograde Wenckebach cycle length (332 ± 69.6 vs 375.5 ± 82.5 ms, p<0.01), a shorter AV node 
refractory period after ablation (261.8 ± 63.7 vs 312.66 ± 77.5 ms, p= 0.04) and persistence of the 
crossover (10.7% vs 2.8%, p= 0.03) were related to a higher incidence of long-term recurrences.  
 
 
Discussion 
Our results show that slow pathway cryoablation for AVNRT is an effective and safe technique, 
with an acute efficacy rate of 99.2% (comparable to that reported by RFCA) and no AV block 
reported. Considering long-term outcome, the incidence of recurrences (11.7%) is higher compared 
to that reported by RFCA, ranging from 2 to 4% [4,7,9,10]. Interestingly, a cooling dynamic pattern 
characterized by longer cooling time during ablation and the presence of residual dual AV node 
physiology appear to be strong predictors of long term AVNRT recurrence.  
Incidence of AV block following AVNRT RFCA has been reported to occur in a percentage of 
patients of about 0.5-2% [7,22,23], and a large meta-analysis reporting an incidence of 1.7% [10]. 
To avoid this risk, cryoablation offers patients a potentially safer alternative to RFCA, due to the 
advantages offered from cryomapping: the transient application of -30°C is useful to assess the 
safety and efficacy of the site, as the appearance of AV block can be completely reversed by 
cryomapping interruption. Recently, a large study including over 1,000 AVNRT patients 
undergoing cryoablation, in fact, confirmed that this technique may present a slightly lower efficacy 
than RFCA, but is indeed safer in terms of incidence of AV block [6]. Indeed, considering the 
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usually young age of the patients and the benign course of AVNRT, the potential higher need of 
repeated procedures following cryoablation may be worth since it is counterbalanced by the clearly 
reduced risk of permanent AV block. The present study confirms these previous findings, but is 
mostly focused on predictor of recurrence, analyzing in addition an original parameter, cooling 
dynamics, which plays a relevant role in influencing long-term outcome of AVNRT cryoablation. 
 
 
Cooling dynamics 
Previous studies investigated the impact of the number and duration of cryoenergy applications on 
cryoablation efficacy, in particular addressing the higher incidence of recurrence compared to 
RFCA [24]. 
This difference is due to the mechanisms of lesion formation of the two energy sources. Compared 
to RFCA, cryoablation produces a smaller and more circumscribed lesion, mainly due to the 
adherence of the catheter to the endocardium during the application [25]. Overall, several factors 
have been investigated. It has been shown that the use of 6-mm tip catheters relates to a lower 
recurrence rate compared to 4-mm tip [11,26]. On the other hand, the role of number and duration 
of cryoenergy applications on long-term outcome is controversial [15,27,28]. Notably, our results 
suggest that the quality of the cooling dynamics may be assessed and seems more relevant 
compared to the general quantity of cryoenergy delivered. The quality of cryoenergy application, 
easily monitored in real time during the procedure, as the time to reach temperature ≤ -70°C and the 
lower minimal absolute temperature, emerged as a strong candidate to improve long-term outcome. 
As showed in Figure 2, despite a certain amount of overlap, likely due to the bias deriving from the 
chosen site for ablation, a longer time to reach target temperature, such as 10 seconds, is likely 
related to ineffective cryoenergy applications. A slower time to reach therapeutic temperature, as 
experienced in many patients suffering from AVNRT recurrences (Figure 3), may in fact be due to 
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a suboptimal contact of the catheter tip to the endocardium, leading to ineffective lesions in the long 
run. Indeed, the presence of a contact force sensing tool, as available for most radiofrequency 
ablation catheters, would probably improve the outcome of the procedure by ensuring optimal 
catheter-tissue contact assessment. However, in the absence of this potential implementation, 
cooling dynamics seems a relevant factor to consider, candidating perhaps, to acutely guide the 
procedure, and, in any case, warranting further prospective investigations.  
 
Residual slow pathway conduction 
Several studies suggest that the persistence of residual slow pathway conduction, identified by EPS 
markers such as AH jump, AV nodal single echo beat and crossover sign, may relate to a higher 
AVNRT recurrence rate. De Sisti et al. [12] in a large series of patients reported that slow pathway 
complete suppression relates to improved outcome, and a single nodal echo beat or residual AH 
jump are associated with a slightly higher incidence of recurrence, and the same results were 
reported by Bastani et al. [29]. Feldman et al. [30] reported that a single AV nodal echo beat did not 
predict AVNRT recurrence, but a large echo window is, indeed, associated with higher risk of 
recurrence.  
The present study shows that residual AH jump and single AV nodal echo beat do not relate to 
higher risk of recurrence (probably due to the small number of patients with residual dual AV node 
physiology compared to the baseline population), but the persistence of crossover sign, when 
present, is significantly related with AVNRT recurrence. In fact, crossover is reported as a specific 
sign of dual AV node physiology, though not strongly sensitive. Moreover, a shorter Wenckebach 
cycle length and a shorter AV node refractory period at post-ablation EPS, signs of a residual slow 
pathway dormant conduction, relate to higher incidence of recurrence. Additionally, merging 
together the aforementioned markers of dual AV node physiology, Kaplan-Meier estimate of 
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survival reports a lower incidence of AVNRT recurrence in patients with none compared to those 
with at least one of these marker (p=0.05). Our data suggest therefore that a more aggressive 
strategy directed to complete elimination of dual AV node physiology (absence of AH jump, single 
nodal echo beat and crossover) could potentially improve long-term efficacy.  
 
Limitations 
The retrospective nature of the study may limit its strength due to the absence of a prospective 
design and follow-up. However, the inclusion of all patients referred for AVNRT ablation, in two 
centers that regularly perform cryoablation in all patients as first-line treatment, avoids the possible 
bias deriving from individual energy source choice following the demonstration of patients’ 
anatomy. The relatively limited number of included patients may have impacted the statistical 
relevance of some EPS parameters. Additionally, the design of the study does not permit to define a 
cut-off for time to target temperature aiming to guarantee an effective lesion; however, longer time 
intervals (more than 10 seconds) to reach target temperature could, indeed, identify ineffective 
applications. The role of these markers of adherence to the target tissue, based on the temperature 
outputs derived from the commercial cryo-console, however, need to be prospectively tested to 
precisely define their role in predicting long-term outcome. 
 
 
Conclusions 
Transcatheter cryoablation of the slow pathway in patients suffering from AVNRT is a safe and 
effective procedure, and it is likely to be reproducibly performed without relevant risks. Although 
characterized by a relatively low incidence of long-term recurrences, its long-term efficacy is lower 
than RFCA. New predictors, such as complete elimination of dual AV node physiology and 
especially an improvement in cooling dynamics quality assessed by a short time interval to reach 
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the therapeutic temperature of <-70°C, will likely be related to an improvement in long-term 
outcome of AVNRT cryoablation. 
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Table 1. Comparison of baseline characteristics between patients without vs. with AVNRT 
recurrence. 
AF= Atrial Fibrillation; AET= Atrial Ectopic Tachycardia; WPW= Wolff-Parkinson-White; 
LVEF= Left Ventricular Ejection Fraction; AADs = antiarrhythmic drugs; AVNRT = 
AtrioVentricular Nodal Reetrant Tachycardia. 
  Total  
(n=239) 
No recurrence 
(n=211) 
Recurrence 
(n=28) p-value 
  
Males, n (%) 90 (37.6) 79 (37.4) 11 (39.3)  0.85 
Age, years 47.5 ± 19.7 48.4 ± 19.5 41 ± 20.1 0.06 
Hypertension, n (%) 57 (23.8) 52 (24.6) 5 (17.8) 0.42 
Hyperthyroidism, n (%) 5 (2.1) 5 (2.4) 0 (0.0) 0.41 
Hypothyroidism, n (%) 13 (5.4) 10 (4.7) 3 (10.7) 0.19 
Structural heart disease, n (%) 18 (7.5) 15 (7.1) 3 (10.7) 0.49 
Associated arrhythmias, n (%) 22 (9.2) 20 (9.5) 2 (7.1) 1.00 
AF, n  15 15 0 0.13 
            AET, n  2 2 0 0.60 
WPW, n  1 0 1 0.11 
Atrial Flutter, n  1 1 0 0.11 
AV block, n 2 2 0 0.60 
LVEF (%) 61.5 ± 6.6 61.2 ± 7.2 62.6 ± 7.2 0.50 
AADs   
Class IC, n (%) 48 (20.1) 44 (20.8) 4 (14.3) 0.38 
Beta-blockers, n (%) 107 (44.7) 94 (44.5) 13 (46.4) 0.85 
Calcium-channel blockers, n (%) 25 (10.5) 22 (10.4) 3 (10.7) 0.96 
19 
 
Type of AVNRT         
Typical, n (%) 227 (94.9) 201 (95.3) 26 (92.8) 0.58 
Atypical, n (%) 12 (5.0) 10 (4.7) 2 (7.1) 0.58 
Symptomatic episodes /year, n 24.9 ± 52.6 24.8 ± 49.6 25 ± 70 0.96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
 
 
 
Table 2. Comparison of baseline electrophysiological study parameters between patients without 
vs. with AVNRT recurrence. 
AA= Atrial-atrial; AH= Atrial-His; HV= His-Ventricular; AVNERP= Atrio-Ventricular Node 
Effective Refractory Period; AVNRT= Atrio-Ventricular Nodal Reentrant Tachycardia; WBCL= 
Wenckebach block cycle length. 
 
  No recurrence 
(n=211) 
Recurrence 
(n=28) 
p-value 
  
Baseline intervals       
AA, (ms) 829.8 ± 163.41 738 ± 172.3 0.01 
AH, (ms) 86 ± 27 80.6 ± 26.5 0.37 
HV, (ms) 42.8 ± 8.7 46.4 ± 8.9 0.82 
Sustained AVNRT induction, n (%) 182 (86.2) 21 (75) 0.19 
Programmed ventricular stimulation 
AVNERP, (ms) 271.3 ± 75.6 280 ± 90 0.60 
AH Jump, n (%) 29 (13.7) 3 (10.7) 0.69 
AVNRT induction, n (%) 6 (2.8) 0 (0.0) 0.37 
AVNRT induction on isoproterenol, n (%)  0 (0.0) 0 (0.0) - 
Programmed atrial stimulation 
AVNERP, (ms) 278.9 ± 74.5 257. 8 ± 47.7 0.30 
AH Jump, n (%) 202 (95.7) 24 (85.7) 0.12 
AVNRT induction, n (%) 133 (63) 14 (50) 0.16 
AVNRT induction on isoproterenol, n (%)  43 (20.4) 7 (25) 0.84 
Incremental atrial pacing 
21 
 
WBCL, ms 356.9 ± 76.3 325.4 ± 54.02 0.05 
Crossover sign, n (%) 76 (36) 13 (46.4) 0.44 
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Table 3. Comparison of cooling dynamics parameters between patients without vs. with AVNRT 
recurrence. T= temperature; AVNRT: atrioventricular node reentrant tachycardia. 
 
Total  
(n=239) 
No recurrence 
(n=211) 
Recurrence 
(n=28) 
p-value 
  
Cryoenergy applications, n 3.3 ± 2.8 3.2 ± 2.9 3.6 ± 2.4 0.54 
Ineffective applications, n 1.4 ± 1.9 1.2 ± 1.7 1.7 ± 1.4 0.45 
Duration of cryoablation, min 18.9 ± 10.3 18.8 ± 10.6 19.5 ± 8.7 0.49 
Effective Cryoenergy application   
Duration, min 7.9 ± 0.5 7.9 ± 0.4 7.7 ± 0.7 0.13 
Time to reach T ≤ -70°C, sec 7.5 ± 2.9 7.3 ± 2.5 8.9 ± 4.4 0.03 
Minimal absolute temperature, °C -79.0 ± 2.4 -79.2 ± 2.3 -78.0 ± 2.5 0.04 
Cooling curve inversion, n (%) 36 (15) 30 (14.2) 6 (21.4) 0.74 
Fluoroscopy time, min 4.5 ± 5.0 4.8 ± 5.3 2.8 ± 2.8 0.25 
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Table 4. Comparison of post-ablation electrophysiological study parameters between patients 
without vs. with AVNRT recurrence. * = cryomodulation of the AV nodal slow pathway. 
AA= Atrial-Atrial; AH= Atrial-His; HV= His-Ventricular; AVNERP= AtrioVentricular Node 
Effective Refractory Period; AVNRT= Atrio-Ventricular Nodal Reentrant Tachycardia; WBCL= 
Wenckebach block cycle length. 
 
  No recurrence 
(n=211) 
Recurrence 
(n=28) 
p-value 
  
Baseline intervals       
AA, (ms) 826 ± 187.8 843 ±204.8 0.83 
AH, (ms) 87 ± 31.3 92.2 ± 33.4 0.65 
HV, (ms) 44.3 ± 7.9 49 ± 7.4 0.15 
Programmed ventricular stimulation   
AVNERP, (ms) 282 ± 62 290 ± 60 0.23 
AH Jump, n (%) 2 (0.9) 0 (0.0) 0.13 
AVNRT induction, n (%) 0 (0.0) 0 (0.0) - 
AVNRT induction on isoproterenol, n (%)  0 (0.0) 0 (0.0) - 
Programmed atrial stimulation   
AVNERP, (ms) 312.6 ± 77.5 261.8 ± 63.7 0.04 
AH Jump, n (%) 42 ( 19.9) 9 (32.1) 0.13 
AVNRT induction, n (%) 1* (0.5) 0 (0.0) 0.72 
AVNRT induction on isoproterenol, n (%)  0 (0.0) 0 (0.0) - 
AV nodal single echo beat n (%)  18 (8.5) 1 (3.6) 0.38 
Incremental atrial pacing   
WBCL, ms 375.5 ± 82.5 332 ± 69.6 <0.01 
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Kay sign, n (%) 6 (2.8) 3 (10.7) 0.03 
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Table 5. Multivariate analysis of parameters related to long-term recurrence. 
AA= Atrial-Atrial; WBCL= Wenckebach block cycle length; AVNERP= atrioventricular node 
effectice refractory period. OR: odds ratio. CI: confidence interval. 
 
OR 95% CI p-value 
Baseline AA interval, pre-ablation 0.99 0.98 - 1.00 0.28 
WBCL, pre-ablation 0.98 0.97 - 1.003 0.13 
WBCL, post-ablation 0.98 0.97 - 1.002 0.10 
Time to reach T ≤ -70°C  1.75 1.01 - 3.03 0.04 
Minimal temperature reached 0.12 0.87 - 3.13 0.12 
Persistence of Kay sign 19.54 0.89 - 428.83 0.06 
AVNERP, post-ablation 1.00 0.98 - 1.02 0.64 
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Figure legends 
Figure 1. Kaplan-Meier estimate of freedom from arrhythmic recurrence of patients undergoing 
AVNRT cryoablation, stratified for the residual presence of none, one or two markers of dual AV 
node physiology (AV nodal single echo beat, AH Jump and Kay sign).  
 
Figure 2. Distribution of time intervals to reach target temperature (-70°C) among the study 
population. Median, interquartile range and minimum/maximum values are represented both for 
patients without recurrence (n= 211) and for patients with recurrence (n= 28). 
 
Figure 3. Comparison between cooling dynamic curves (starting from cryomapping at -30°C to 
cryoablation at -70°C) of two different patients respectively experiencing long-term freedom from 
arrhythmias (light-blue) and early AVNRT recurrence (blue). 
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Figure 1. 
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Figure 2. 
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Figure 3. 
 
